Deep Tech Startups

Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.

1 investor

Enhanced Drilling produces EC-Monitor, a real-time well monitoring system that tracks volume fluctuations and detects anomalies in drilling operations. The system is designed for offshore and deepwater drilling environments where precise pressure and kick/loss detection are critical for safety.

1 investor

Enigma develops robotics foundation AI models, a hardware-agnostic abstraction layer, and user interfaces that let humans control and interact with robots. Its technology is designed to run on any robot form factor, from warehouse arms to humanoids, and is sold to robotics hardware companies that build the physical machines.

1 investor

Enjamb develops an agentic AI platform for biopharma R&D teams that automates drug discovery, trial execution, and regulatory filings. The platform integrates with existing systems to support programs from early discovery through FDA approval.

1 investor

Ennoventure provides covert, cryptographic authentication signals embedded invisibly into product packaging artwork using standard printing equipment and conventional inks, verifiable via any smartphone. It serves brands for anti-counterfeiting and brand protection, offering AI-based verification, market intelligence analytics, and integration through APIs and SDKs.

1 investor

ENPICOM provides a software platform for biologics discovery that orchestrates analysis workflows, handles immune-repertoire and antibody sequence analysis, and integrates assay and sequencing data for drug development scientists and teams. The platform processes billions of sequences and delivers results directly to scientists without requiring dedicated bioinformatics support.

1 investor

ENSEM Therapeutics develops small molecule precision medicines for oncology using its Kinetic Ensemble platform, which combines computational and AI/deep learning methods with experimental techniques to identify cryptic binding pockets. The company focuses on structure-based drug design for high-value, difficult-to-drug targets.

1 investor

Entact is a drug discovery company developing treatments for patients. It works in the biotechnology and therapeutics sector.

1 investor

Enthought provides scientific computing services, enterprise scientific software development, and digital transformation for science, applying Python, AI/machine learning, and simulation to research and R&D problems. It serves organizations in sectors such as pharmaceuticals, materials, and semiconductors, with operations in the U.S. and Japan.

1 investor

Enumera Molecular develops technology and a platform for simplified, lower-cost workflows that enable liquid biopsy and high-dimensional omics assays for laboratories. It targets clinical labs performing molecular diagnostics.

1 investor

Countable Labs (formerly Enumerix) develops a digital PCR platform that performs genetic analysis with higher sensitivity, precision, and dynamic range than legacy PCR methods. The technology serves oncology, NIPT (non-invasive prenatal testing), infectious disease, and cell and gene therapy applications.

1 investor

Enuvio manufactures microfluidic devices for cell co-culture and compartmentalization research, including neuronal co-culture, axon guidance, and chemotaxis platforms for life sciences researchers.

1 investor

Envisioning Labs is a deep tech innovation firm that co-develops technologies to counter climate change and reduce greenhouse gas emissions, working across sectors such as mining, wildfire detection, marine conservation, and advanced manufacturing. Its work includes CoreBurst, a gas-based thermodynamic ore-grinding process (spun off as Rockburst Technologies), wildfire and peat-fire detection systems, and non-acoustic Lidar depth finders for marine navigation.

1 investor

Enyx, now part of Exegy, builds FPGA-based low-latency solutions for financial trading, including market data acquisition and distribution, order execution, and network connectivity management. Its products serve trading firms and financial technology applications across the trading lifecycle.

1 investor

Enzidia operates an enzyme engineering platform that combines ultra-high-throughput screening (its MillionFull technology) with AI-directed evolutionary loops to optimize enzymes and cell factory strains for biomanufacturing. It partners with industrial biotech companies to improve bioprocess efficiency and generate large labeled enzyme sequence-performance datasets.

1 investor

Enzymlogic provides kinetic profiling of compounds to support early-stage drug discovery, focusing on the Hit to Lead and Lead Optimization phases. Using protein science and high-throughput screening assays, it delivers kinetic data on compound-target interactions to pharmaceutical and biotech organizations to help them prioritize promising molecules.

1 investor

EO is a verification and intelligence layer for deployed GPU compute infrastructure, converting fragmented hardware telemetry into a continuously verified record of each asset's identity, condition, custody, degradation, and economic value. It serves compute operators, capital providers, insurers, and hardware buyers, providing a shared state layer used for financing, optimization, insurance, resale, and servicing.

1 investor

EODev is a French industrial company specializing in zero-emission energy production and storage systems, with a focus on hydrogen-powered technologies and battery systems for stationary, mobile, and marine applications. The company serves manufacturers, local authorities, and industrial sectors seeking to transition to decarbonized solutions for mobility and heavy industries.

1 investor

Eon develops brain emulation technology, having built a digital emulation of a fruit fly brain — 139,255 neurons and 50 million connections preserved, scanned, and reconstructed — that reproduces biological neural responses and behaviors such as navigating, grooming, and feeding. The company aims to solve brain emulation as an engineering effort in the context of a future with superintelligence.

1 investor

EOS develops additive manufacturing (industrial 3D printing) technology and materials, offering tools such as a carbon footprint calculator and carbon-neutral or carbon-reduced materials to help manufacturers produce more sustainably. It positions itself around "responsible manufacturing" and serves industrial production customers.

1 investor

EOS SAR develops synthetic aperture radar (SAR) payloads for a constellation of remote sensing satellites, alongside optical satellites operating in tandem in low Earth orbit. It aims to provide high-resolution Earth observation imagery (down to 0.25m) and analytics for any location, day or night and through cloud cover.

1 investor

Eos BioInnovation invests in early-stage regenerative medicine therapies and technologies, focusing on cell, gene, and tissue therapies that target disease causes. The firm partners with researchers and entrepreneurs to accelerate the translation of breakthrough science into commercial biotech companies.

1 investor

Ephemeris Net is building networking infrastructure for space-based internet, aiming to define how data moves through space beyond traditional bent-pipe satellite systems.

1 investor

Ephemeron Labs provides hardware and software accessories that add EBIC (electron-beam-induced current) measurement capability to scanning electron microscopes, including sensitive preamplifiers, sample interfacing and shielding, and a scan controller. Its systems support femtoampere-sensitivity current imaging of solid-state devices such as solar cells and nanowires for researchers doing materials and semiconductor characterization.

1 investor